Biopharmaceutical companies in Israel and the United States are collaborating on the development of new cannabinoid-based cancer treatments.
Bethesda, Maryland-based Cannabics Pharmaceuticals last week announced the signing of a memorandum of understanding with Herzliya, Israel-based Cannomed Medical Cannabis Industries Ltd. to develop cannabis cultivars to treat various types of cancers.
Through the partnership, Cannabics will expand its portfolio of cannabis compositions, which will be extracted from Cannomed’s current collection of 17 proprietary strains.
Cannomed’s proprietary strains will be evaluated for their anti-tumor potential during the collaborative research.
“Cannomed and Cannabics will collaborate to develop cannabinoid products based on Cannomed’s cannabis cultivars,” says Cannabics co-founder and CTO Dr. Eyal Ballan. “We have seen in the past similar collaborations yielding valuable data in pre-clinical studies held at our facility, and we are looking forward to revealing what anti-tumor potential Cannomed’s strains may hold.”
Throughout the research, Cannabics will utilize its High Throughput Screening (HTS) facility in Israel to perform the cannabis extractions and examine the anti-tumor effects of cannabinoids on various types of human cancer cells.
With the HTS process, automated equipment can rapidly test thousands to millions of samples for biological activity at the model organism, cellular, pathway, and molecular levels.
Cannomed co-founder and CEO, Kfir Gindi says that the company is excited to explore the medicinal qualities of their proprietary cannabis strains with Cannabics and potentially develop new cannabis-based medicines for regulated European markets.